Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In the SUSTAIN 6 trial, over 3,297 patients with type 2 diabetes with established chronic kidney disease and/or cardiovascular disease underwent randomization to semaglutide or placebo and were followed for 2 years resulting in a 26% risk reduction in the combined endpoint of rate of cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke [47]
For Tirzepatide users specifically, GHK-Cu becomes relevant as weight loss progresses
If an article focuses only on retinal risk, patients may miss the larger medical picture
That is not good for your skin's overall health
00:12:52 Steve Small: Yeah, well have to wait and see
The clinical impact varies by individual
